Open Access

REVIEW

Updated thoughts on SARS-CoV-2 and coronavirus therapies, fighting and surviving

WENJUAN LI^*, GE SONG

Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, USA

* Address correspondence to: Wenjuan Li,

BIOCELL 2020, 44(2), 127-135. https://doi.org/10.32604/biocell.2020.010018

Received 04 February 2020; Accepted 08 April 2020; Issue published 27 May 2020

Abstract

From late December 2019 a new human-adapted coronavirus, SARS-CoV-2, was observed and isolated in clustered patients in Wuhan, China. It has been proved to be able to transmit human-to-human and cause pneumonia, leading to about 2% fatality. Its genome characteristics, immune responses and related potential treatments, such as chemical drugs, serum transfusion and vaccines including DNA vaccines, are discussed in this review for a brief summary.

---

Keywords

---